Pharmaceuticals · ALPM
Pharma - Formulators
from 809 today
Alembic Pharma delivered a better-than-expected financial performance in 1QFY27, driven by outperformance in the US and strong growth in export formulations and the API segment. We reiterate our Neutral rating on the stock as the current valuation provides limited upside, while valuing ALPM at 17x 12M forward earnings to arrive at our TP of INR845.
Ratings and target prices as published by each firm. Each summary condenses that firm's stated view in its own note and is attributed to it; no report text is reproduced.
